Ovarian and Uterine Carcinosarcomas: A Comparative Analysis of Prognostic Variables and Survival Outcomes
暂无分享,去创建一个
A. Munkarah | C. Bryant | Sanjeev Kumar | J. Shah | G. Garg | R. Morris
[1] L. Cantrell,et al. Carcinosarcoma of the Ovary: A Review , 2009, Obstetrical & gynecological survey.
[2] A. Lopes,et al. Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcoma. , 2009, European journal of obstetrics, gynecology, and reproductive biology.
[3] Jason D. Wright,et al. The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. , 2008, American journal of obstetrics and gynecology.
[4] A. Iasonos,et al. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. , 2008, Gynecologic oncology.
[5] N. Mitra,et al. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. , 2008, Gynecologic oncology.
[6] D. Gaffney,et al. The impact of adjuvant radiation therapy on survival in women with uterine carcinosarcoma. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[7] V. Seshan,et al. Uterine Carcinosarcomas and Grade 3 Endometrioid Cancers: Evidence for Distinct Tumor Behavior , 2008, Obstetrics and gynecology.
[8] J. Diebold,et al. Molecular genetic aberrations of ovarian and uterine carcinosarcomas—a CGH and FISH study , 2008, Virchows Archiv.
[9] J. Wolf,et al. A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary. , 2007, Gynecologic oncology.
[10] G. Mor,et al. Carcinosarcoma of the ovary , 2007, International Journal of Gynecologic Cancer.
[11] S. Temkin,et al. Early-stage carcinosarcoma of the uterus: the significance of lymph node count , 2006, International Journal of Gynecologic Cancer.
[12] L. Downs,et al. Clinical features and outcomes of uterine and ovarian carcinosarcoma. , 2006, Gynecologic oncology.
[13] J. Boyd,et al. Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer , 2005, Clinical Cancer Research.
[14] J. Thigpen,et al. Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. , 2004, Gynecologic oncology.
[15] M. Zhan,et al. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. , 2004, Gynecologic oncology.
[16] G. Jayson,et al. Carcinosarcoma of the ovary , 2003, British Journal of Cancer.
[17] E. Oliva,et al. Paclitaxel and platinum chemotherapy for malignant mixed müllerian tumors of the ovary. , 2002, Gynecologic oncology.
[18] N. Hacker,et al. Multimodality therapy for patients with clinical Stage I and II malignant mixed Müllerian tumors of the uterus , 2001, Cancer.
[19] B. Monk,et al. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus , 2000, Cancer.
[20] R. Caduff,et al. Comparative analysis of histologic homologues of endometrial and ovarian carcinoma. , 1998, The American journal of surgical pathology.
[21] A. Gadducci,et al. Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. , 1997, Gynecologic oncology.
[22] N. Weiss,et al. The epidemiology of sarcomas of the uterus. , 1986, Journal of the National Cancer Institute.
[23] E. Topuz,et al. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum. , 2008, Gynecologic oncology.
[24] M. Dimopoulos,et al. Clinicopathological features of ovarian carcinosarcomas: a single institution experience. , 2005, Gynecologic oncology.